• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Budesonide-formoterol as needed superior to terbutaline in mild asthma: The SYGMA trial

byJames RoebkerandDayton McMillan
May 24, 2018
in Chronic Disease, Emergency, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with mild asthma, use of the inhaled combined corticosteroid (ICS) and beta agonist budesonide-formoterol as needed was superior to terbutaline as needed with respect to electronically recorded weeks of well-controlled asthma.

2. While budesonide-formoterol as needed was inferior to twice daily budesonide maintenance therapy with respect to weeks of well-controlled asthma, there was no significant difference in rates of exacerbations.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Low symptom burden and sporadic nature of exacerbations often make adherence to ICS maintenance therapy challenging in patients with mild asthma. When this produces over-dependence on short-acting beta agonists (SABA) for symptom relief, airway inflammation goes untreated and patients are at risk for future exacerbations. In the SYmbicort Given as needed in Mild Asthma (SYGMA) trial, efficacy and safety of budesonide-formoterol (a combination ICS and beta-agonist) on an as needed basis was comparted to both the beta-agonist terbutaline as needed and with maintenance budesonide plus terbutaline as needed. The primary endpoint, superiority of as needed budesonide-formoterol to terbutaline with regard to electronically recorded weeks of well-controlled asthma, demonstrated a greater percentage of weeks with asthma control over a 52 week period for budesonide-formoterol patients. However, budesonide-formoterol was inferior to budesonide maintenance therapy with regard to weeks of well-controlled asthma (secondary endpoint).

A strength of this randomized, double-blind, 52-week, parallel group trial was the long duration, which allowed reliable assessment of asthma exacerbations. The study also used a 2-4 week run-in period to collect baseline data and ensure subjects required step 2 asthma treatment. Though the high rate of adherence in the trial allowed appropriate comparison with budesonide maintenance therapy, it limits the generalizability to the real-world population where adherence rates may be lower.

Click to read the study, published in NEJM

 Relevant Reading: Daily versus as-needed corticosteroids for mild persistent asthma

RELATED REPORTS

Methylprednisolone after hip replacement surgery improves pain and sleep quality

Emergency department crowding negative influences outcomes for adults presenting with asthma

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

In-Depth [randomized controlled trial]: This was a phase III, double-blind, parallel-group, multicenter trial that randomized 3849 patients to twice daily placebo plus budesonide-formoterol (200 mg of budesonide and 6 mg formoterol) as needed (n = 1279), twice-daily placebo plus terbutaline (0.5 mg) as needed (n = 1280), or twice daily budesonide (200 mg) maintenance therapy plus terbutaline (0.5 mg) as needed (n = 1290). Eligible patients were 12 or older and had clinically mild asthma. Patients with exacerbations or long-term poor control were permitted to receive additional open-label treatment with twice daily budesonide (200 mg) at the investigator’s discretion. The primary endpoint was to demonstrate superiority of budesonide-formoterol as needed compared to terbutaline as needed for asthma control, measured by electronically recorded weeks with well-controlled asthma over a 52-week period. Secondary endpoint included noninferiority of budesonide-formoterol to budesonide maintenance therapy, rates of severe exacerbations and time to the first severe exacerbation, and Asthma-Control Questionnaire-5 (ACQ-5) score.

Patients in the budesonide-formoterol as needed group had well-controlled asthma 34.4% of weeks, compared to 31.1% in the terbutaline group (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.00 to 1.30; p = 0.046). This percentage was inferior compared to budesonide maintenance therapy (34.4% vs. 44.4%; OR, 0.64; 95%CI, 0.57 to 0.73). Budesonide-formoterol resulted in a 64% lower rate of severe exacerbations compared to terbutaline (annual exacerbation rate, 0.07 vs. 0.20; rate ratio, 0.36; 95%CI, 0.27 to 0.49) and also the time to the first severe exacerbation (hazard ratio [HR], 0.44; 95%CI, 0.33 to 0.58). Neither rates of severe exacerbations nor time to first exacerbation differed significantly between budesonide-formoterol as needed and budesonide maintenance therapy. Differences in the change in the ACQ-5 score were in favor of the budesonide-formoterol group compared to terbutaline, and in favor of budesonide maintenance compared to budesonide-formoterol. Adverse events were more frequent in the terbutaline as needed group, but there were no notable differences in the side effect profile between treatment groups.

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmacorticosteroid
Previous Post

Amyloid-beta (1-40) is a strong predictor of mortality in acute coronary syndrome

Next Post

Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndrome

RelatedReports

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Surgery

Methylprednisolone after hip replacement surgery improves pain and sleep quality

January 24, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Emergency department crowding negative influences outcomes for adults presenting with asthma

December 27, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

December 14, 2022
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Chronic Disease

  Vitamin C supplementation in pregnancy improves respiratory function in children of smoking mothers at 5 years of age

December 7, 2022
Next Post
Parental cannabis use increasing, cigarette use decreasing

Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndrome

Being overweight and obese associated with increased incidence of chronic kidney disease

2 Minute Medicine Rewind May 28, 2018

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Physicians report feeling moral distress over hospital policies that force inadequate care based on immigration status

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options